The CD8+ cytotoxic T lymphocyte (CTL) response has an important protective role in the immunopathogenesis of HIV-1 infection, and is a key focus of vaccine development. However, the factors that determine the effectiveness of CTL against HIV-1 remain poorly understood. Unlike current vaccines that mimic naturally protective immunity, a successful HIV-1 vaccine will need to elicit CTL responses that are superior to those in natural infection. We hypothesize that HIV-1 mutational escape from CTL, particular in early infection, initiates a cascade of events that dooms the HIV-1-specific CTL response to long term failure. Early escape puts the CTL response a step behind HIV-1, allowing early events including irreversible CD4+ T cell depletion and original antigenic sin. Thus, addressing basic questions about the function and interaction of HIV-1-specific CTL with infected cells is key to the rationale design of a vaccine that will target CTL responses to avoid the naturally occurring mechanisms of failure. Our prior research has established in vitro models using HIV-1-infected cells to test questions that are difficult to address with correlative studies in vivo, e.g. that early protein epitopes can be recognized earlier in the life cycle than late protein epitopes. For this third funding period of the grant, we propose to continue examining factors affecting the interaction of CTL and HIV-1 using these systems, as well as to extend our studies to in vivo correlations. Specifically, we aim: 1. To assess for differential fitness costs involved in early and late CTL escape after HIV-1 infection;2. To determine whether epitope avidity thresholds change over the course of infection or correlate to susceptibility to CTL escape;3. To investigate the role of TCR breadth in preventing HIV-1 escape from CTL.

Public Health Relevance

Historically successful vaccines have worked against pathogens where survivors of infection develop protective immunity by mimicking this natural immunity;for HIV-1, infected persons generally fail to contain the virus, and thus a vaccine that mimics natural immune responses against HIV-1 will likely fail. The goal of this project is to continue our ongoing studies to explore mechanisms of failure of the cellular immune response to contain HIV-1 infection. Understanding these mechanisms may be important for designing vaccine strategies that promote more effective responses than occur in nature.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI043203-16
Application #
8238388
Study Section
AIDS Immunology and Pathogenesis Study Section (AIP)
Program Officer
Embry, Alan C
Project Start
1998-04-01
Project End
2013-03-31
Budget Start
2012-04-01
Budget End
2013-03-31
Support Year
16
Fiscal Year
2012
Total Cost
$403,787
Indirect Cost
$133,651
Name
University of California Los Angeles
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Wu, Nicholas C; De La Cruz, Justin; Al-Mawsawi, Laith Q et al. (2014) HIV-1 quasispecies delineation by tag linkage deep sequencing. PLoS One 9:e97505
Al-Mawsawi, Laith Q; Wu, Nicholas C; De La Cruz, Justin et al. (2014) Short communication: HIV-1 gag genetic variation in a single acutely infected participant defined by high-resolution deep sequencing. AIDS Res Hum Retroviruses 30:806-11
De La Cruz, Justin; Vollbrecht, Thomas; Frohnen, Patricia et al. (2014) Ineffectual targeting of HIV-1 Nef by cytotoxic T lymphocytes in acute infection results in no functional impairment or viremia reduction. J Virol 88:7881-92
Harris, D T; Badowski, M; Balamurugan, A et al. (2013) Long-term human immune system reconstitution in non-obese diabetic (NOD)-Rag (-)-? chain (-) (NRG) mice is similar but not identical to the original stem cell donor. Clin Exp Immunol 174:402-13
Bhattacharya, Debika; Lewis, Martha J; Lassmann, Britta et al. (2013) Combination of allele-specific detection techniques to quantify minority resistance variants in hepatitis B infection: a novel approach. J Virol Methods 190:34-40
Balamurugan, Arumugam; Ali, Ayub; Boucau, Julie et al. (2013) HIV-1 gag cytotoxic T lymphocyte epitopes vary in presentation kinetics relative to HLA class I downregulation. J Virol 87:8726-34
Kitchen, Scott G; Levin, Bernard R; Bristol, Gregory et al. (2012) In vivo suppression of HIV by antigen specific T cells derived from engineered hematopoietic stem cells. PLoS Pathog 8:e1002649
Lewis, Martha J; Dagarag, Mirabelle; Khan, Basim et al. (2012) Partial escape of HIV-1 from cytotoxic T lymphocytes during chronic infection. J Virol 86:7459-63
Chen, Diana Y; Balamurugan, Arumugam; Ng, Hwee L et al. (2011) Antiviral activity of human immunodeficiency virus type 1 Gag-specific cytotoxic T lymphocyte targeting is not necessarily intrinsically superior to envelope targeting. J Virol 85:2474-8
Yang, Otto O; Daar, Eric S; Ng, Hwee L et al. (2011) Increasing CTL targeting of conserved sequences during early HIV-1 infection is correlated to decreasing viremia. AIDS Res Hum Retroviruses 27:391-8

Showing the most recent 10 out of 46 publications